Chemicals Valuations and M&A Backdrop, Recovery in Sight?

The chemicals M&A market enters Q2 2026 in a state of constructive tension. Deal activity has recovered meaningfully from the lows of 2022–2023, with transaction volumes up 18% in 2025, yet fresh geopolitical uncertainty, centred on US-Iran conflict and Strait of Hormuz disruptions, is creating a more cautious mood among buyers and compressing earnings visibility for European producers.

Valuations are holding but geography increasingly determines price: US-listed peers trade at premiums of up to 5x EV/EBITDA over European counterparts in the most feedstock-intensive segments, while businesses with differentiated IP or contract manufacturing capability face a smaller discount.

Deal-Making is Picking Up but the Mood is Cautious

After a difficult 2022–2023, when rising interest rates, destocking, and macro uncertainty suppressed deal activity to decade lows, the chemicals M&A market has recovered meaningfully. Data from Dealogic and MergerMarket suggest 18% chemicals deal value increase in 2025.

Several structural forces are converging to create this environment:

• Interest rates have stabilised, reducing financing costs and unlocking deal capacity.
• Private equity funds are sitting on $300bn+ of committed but undeployed capital. The pressure to put it to work is building. PE-backed chemicals platforms such as Azelis, IMCD, and HEXPOL are actively hunting bolt-ons.
• Corporate chemicals players are rationalising portfolios. Shell has initiated a strategic review of its chemicals operations. BASF has continued with smaller carve-outs. LyondellBasell sold four European petrochemical plants to AEQUITA.
• Strategic acquirers account for two thirds of all chemicals transactions. They are increasingly focused on smaller deals with low integration risk – targeted capability additions are more attractive than transformational deals in the current environment.

That momentum has, however, run into a fresh headwind. Escalating geopolitical tensions – including US-Iran developments and wider Middle East instability – are pushing up feedstock and energy costs and creating uncertainty around forward earnings visibility. This is affecting European businesses more acutely than US ones, for reasons discussed below.

The Gap Between US and European Chemicals Valuations Persists

The data reveals a fault line running through European chemicals valuations. US-listed peers command a meaningful premium to their European counterparts on 2026E EV/EBITDA consensus multiples, with the gap widest in the most feedstock-intensive segments. Commodity chemicals shows the starkest divergence – reflecting the structural energy and feedstock cost disadvantage facing European producers. Specialty chemicals tells a similar story, with the gap narrowing only for businesses with genuinely differentiated IP (e.g. Croda UK at 10.6x). Flavours and fragrances and paints and coatings show more modest gaps, partly because the leaders compete on global brand and formulation strength. Industrial gases and petrochemicals are at near-parity as global pricing mechanisms and integrated business models largely neutralise the geography premium.

Scarcity of Chemicals Custom/Contract Manufacturers

The custom manufacturing model in chemicals has largely been built out in Europe and Switzerland – Lonza at 17.6x, Dottikon at 30.8x, Siegfried at 12.4x dominate because they grew up alongside the European pharma industry (Novartis, Roche, Bayer), which historically outsourced API and speciality chemistry manufacturing close to home. The US equivalent tends to be either fully captive (in-house at large pharma) or handled by pharma-specific CDMOs that sit in healthcare rather than chemicals classifications.

Custom manufacturers are genuinely scarce assets globally, and buyers looking for this capability have limited domestic acquisition targets. That scarcity premium is precisely why these businesses command the highest multiples in the sector.

Where the Money Flows: A Subsector View

The twelve months to April 2026 produced stark divergence across chemicals subsectors.

• Fertilizers and commodity chemicals averaged year-on-year share price gains of +34% and +33% respectively, figures that reflect a supply shock rather than fundamental earnings recovery. Nitrogen and ammonia flows through the Strait were severely curtailed, lifting prices sharply: Yara surged 87%, CF Industries 52% and Nutrien 36%, while Tronox and Celanese both rebounded from lows.
• Specialty chemicals averaged +27%, but this is heavily distorted by two company-specific restructuring recoveries, Ingevity +143% and Mativ +111%, rather than a broad sectoral tailwind.
• Custom manufacturing averaged +24%, driven by Dottikon which returned +85% on contract wins, while Lonza and Siegfried were flat on softer pharma capex.
• Petrochemicals (+15%) tells a geopolitical story, with US Gulf Coast ethylene producers Dow, Westlake and LyondellBasell gaining 20–30% as widening NGL–naphtha spreads eroded the cost position of European and Asian competitors.
• At the other end, crop protection averaged -18% – masking extreme dispersion, with Corteva up 37% on strong seed pricing but FMC down 55% on balance sheet stress and Nufarm -36% on Australian market weakness.
• Chemical distributors fell -15% on average as prolonged destocking across their customer base compressed margins, with Azelis -32% and IMCD -21% both issuing profit warnings during the period.
• Flavours and fragrances declined -5%, with the three large consolidators – Givaudan, Symrise and DSM-Firmenich – all falling 21–28% as volume recovery in consumer goods lagged integration costs and elevated leverage.

What This Means in Practice for Chemicals Business Owners

If any of the following is true, it is worth having a conversation:

• Considering your options and want to understand what your business is worth.
• Received an approach from an acquirer and want to understand whether the terms are reasonable.
• Thinking about succession and want to explore the full range of options – trade sale, management buyout, private equity, or family transfer.

The businesses that achieve the best outcomes are those that approach succession as a strategic process, beginning before any intended transaction. A business prepared for sale – with clean financials, a strong management team, documented processes, and a clear growth narrative – consistently commands higher valuations than one brought to market reactively. Finding the right buyer takes time. A competitive, well-run process almost always produces a better outcome than a bilateral conversation with the only party who happened to knock on the door.

One dimension of the current market worth specific attention is cross-border buyer interest in UK businesses. UK speciality chemicals companies are increasingly appearing on the radar of acquirers from continental Europe, North America, and parts of Asia who are looking to establish or strengthen a UK and broader European market presence. The characteristics they look for are consistent: proprietary formulations or process know-how, established relationships with major customers, regulatory approvals and a strong team. For owners, the implication is that the universe of potential acquirers is wider than it appears. A process that only considers domestic UK buyers is likely to leave significant value on the table.

This article is intended for information purposes only and does not constitute financial, tax or legal advice. Valuation multiples are based on S&P Capital IQ consensus estimates for listed peer groups as of April 2026 and are provided for directional context only. Private company transactions will differ. Specific professional advice should be sought before making any business or financial decisions.